Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1957 1
1982 1
1983 1
1984 1
1985 4
1986 2
1987 2
1988 6
1989 2
1990 6
1991 4
1992 6
1993 9
1994 7
1995 8
1996 7
1997 5
1998 7
1999 10
2000 12
2001 13
2002 14
2003 8
2004 7
2005 24
2006 16
2007 13
2008 15
2009 13
2010 18
2011 20
2012 14
2013 26
2014 25
2015 21
2016 15
2017 14
2018 14
2019 14
2020 17
2021 26
2022 19
2023 13
2024 7
2025 6

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

446 results

Results by year

Filters applied: . Clear all
Page 1
Prevalence of malnutrition in patients at first medical oncology visit: the PreMiO study.
Muscaritoli M, Lucia S, Farcomeni A, Lorusso V, Saracino V, Barone C, Plastino F, Gori S, Magarotto R, Carteni G, Chiurazzi B, Pavese I, Marchetti L, Zagonel V, Bergo E, Tonini G, Imperatori M, Iacono C, Maiorana L, Pinto C, Rubino D, Cavanna L, Di Cicilia R, Gamucci T, Quadrini S, Palazzo S, Minardi S, Merlano M, Colucci G, Marchetti P; PreMiO Study Group. Muscaritoli M, et al. Among authors: lorusso v. Oncotarget. 2017 Aug 10;8(45):79884-79896. doi: 10.18632/oncotarget.20168. eCollection 2017 Oct 3. Oncotarget. 2017. PMID: 29108370 Free PMC article.
Bevacizumab plus capecitabine versus capecitabine alone in elderly patients with previously untreated metastatic colorectal cancer (AVEX): an open-label, randomised phase 3 trial.
Cunningham D, Lang I, Marcuello E, Lorusso V, Ocvirk J, Shin DB, Jonker D, Osborne S, Andre N, Waterkamp D, Saunders MP; AVEX study investigators. Cunningham D, et al. Among authors: lorusso v. Lancet Oncol. 2013 Oct;14(11):1077-1085. doi: 10.1016/S1470-2045(13)70154-2. Epub 2013 Sep 10. Lancet Oncol. 2013. PMID: 24028813 Clinical Trial.
Adjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stage IB-IIIA non-small-cell lung cancer (Adjuvant Navelbine International Trialist Association [ANITA]): a randomised controlled trial.
Douillard JY, Rosell R, De Lena M, Carpagnano F, Ramlau R, Gonzáles-Larriba JL, Grodzki T, Pereira JR, Le Groumellec A, Lorusso V, Clary C, Torres AJ, Dahabreh J, Souquet PJ, Astudillo J, Fournel P, Artal-Cortes A, Jassem J, Koubkova L, His P, Riggi M, Hurteloup P. Douillard JY, et al. Among authors: lorusso v. Lancet Oncol. 2006 Sep;7(9):719-27. doi: 10.1016/S1470-2045(06)70804-X. Lancet Oncol. 2006. PMID: 16945766 Clinical Trial.
High levels of autotaxin and lysophosphatidic acid predict poor outcome in treatment of resectable gastric carcinoma.
Schirizzi A, Donghia R, De Nunzio V, Renna N, Centonze M, De Leonardis G, Lorusso V, Fantasia A, Coletta S, Stabile D, Ferro A, Notarnicola M, Ricci AD, Lotesoriere C, Lahn M, D'Alessandro R, Giannelli G. Schirizzi A, et al. Among authors: lorusso v. Eur J Cancer. 2024 Dec;213:115066. doi: 10.1016/j.ejca.2024.115066. Epub 2024 Oct 13. Eur J Cancer. 2024. PMID: 39426076 Free article.
Methodological assessment of HCC literature.
Daniele G, Costa N, Lorusso V, Costa-Maia J, Pache I, Pirisi M. Daniele G, et al. Among authors: lorusso v. Ann Oncol. 2013 Apr;24 Suppl 2(Suppl 2):ii6-14. doi: 10.1093/annonc/mdt052. Ann Oncol. 2013. PMID: 23715943 Free PMC article. Review.
Multimodal treatment of resectable pancreatic ductal adenocarcinoma.
Silvestris N, Brunetti O, Vasile E, Cellini F, Cataldo I, Pusceddu V, Cattaneo M, Partelli S, Scartozzi M, Aprile G, Casadei Gardini A, Morganti AG, Valentini V, Scarpa A, Falconi M, Calabrese A, Lorusso V, Reni M, Cascinu S. Silvestris N, et al. Among authors: lorusso v. Crit Rev Oncol Hematol. 2017 Mar;111:152-165. doi: 10.1016/j.critrevonc.2017.01.015. Epub 2017 Feb 4. Crit Rev Oncol Hematol. 2017. PMID: 28259290 Free article. Review.
Target therapies in pancreatic carcinoma.
Silvestris N, Gnoni A, Brunetti AE, Vincenti L, Santini D, Tonini G, Merchionne F, Maiello E, Lorusso V, Nardulli P, Azzariti A, Reni M. Silvestris N, et al. Among authors: lorusso v. Curr Med Chem. 2014;21(8):948-65. doi: 10.2174/09298673113209990238. Curr Med Chem. 2014. PMID: 23992319 Review.
Neoadjuvant multimodal treatment of pancreatic ductal adenocarcinoma.
Silvestris N, Longo V, Cellini F, Reni M, Bittoni A, Cataldo I, Partelli S, Falconi M, Scarpa A, Brunetti O, Lorusso V, Santini D, Morganti A, Valentini V, Cascinu S. Silvestris N, et al. Among authors: lorusso v. Crit Rev Oncol Hematol. 2016 Feb;98:309-24. doi: 10.1016/j.critrevonc.2015.11.016. Epub 2015 Nov 23. Crit Rev Oncol Hematol. 2016. PMID: 26653573 Review.
Predictive factors to targeted treatment in gastrointestinal carcinomas.
Silvestris N, Marech I, Brunetti AE, Azzariti A, Numico G, Cicero G, Delcuratolo S, De Luca R, Burz C, Lorusso V. Silvestris N, et al. Among authors: lorusso v. Cancer Biomark. 2014;14(2-3):151-62. doi: 10.3233/CBM-130327. Cancer Biomark. 2014. PMID: 24878816 Free article. Review.
446 results